{"id":"ima901","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IMA901 is an autologous dendritic cell vaccine engineered to present patient-specific neoantigens derived from their tumor's unique mutations. The vaccine is designed to stimulate CD8+ T cell responses against these personalized tumor-associated antigens, enabling the immune system to target and eliminate cancer cells. It is typically used in combination with checkpoint inhibitors like sunitinib to enhance anti-tumor immunity.","oneSentence":"IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:43.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma (in combination with sunitinib)"}]},"trialDetails":[{"nctId":"NCT01265901","phase":"PHASE3","title":"IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Immatics Biotechnologies GmbH","startDate":"2010-12","conditions":"Metastatic Renal Cell Carcinoma","enrollment":339},{"nctId":"NCT00523159","phase":"PHASE2","title":"IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease","status":"COMPLETED","sponsor":"Immatics Biotechnologies GmbH","startDate":"2007-05","conditions":"Renal Cell Carcinoma","enrollment":68}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DEHYDRATION"},{"count":2,"reaction":"HYPONATRAEMIA"},{"count":2,"reaction":"RESPIRATORY FAILURE"},{"count":1,"reaction":"AORTIC THROMBOSIS"},{"count":1,"reaction":"DISSEMINATED INTRAVASCULAR COAGULATION"},{"count":1,"reaction":"EXTREMITY NECROSIS"},{"count":1,"reaction":"HYDROTHORAX"},{"count":1,"reaction":"HYPOCALCAEMIA"},{"count":1,"reaction":"HYPOMAGNESAEMIA"},{"count":1,"reaction":"INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMA901 Vaccine"],"phase":"phase_3","status":"active","brandName":"IMA901","genericName":"IMA901","companyName":"Immatics Biotechnologies GmbH","companyId":"immatics-biotechnologies-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. Used for Metastatic renal cell carcinoma (in combination with sunitinib).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}